U.S. markets open in 7 hours 22 minutes
  • S&P Futures

    3,826.75
    -12.25 (-0.32%)
     
  • Dow Futures

    31,467.00
    +2.00 (+0.01%)
     
  • Nasdaq Futures

    12,528.25
    -135.50 (-1.07%)
     
  • Russell 2000 Futures

    2,191.20
    +1.50 (+0.07%)
     
  • Crude Oil

    67.22
    +1.13 (+1.71%)
     
  • Gold

    1,701.60
    +3.10 (+0.18%)
     
  • Silver

    25.51
    +0.22 (+0.88%)
     
  • EUR/USD

    1.1899
    -0.0026 (-0.21%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3818
    -0.0010 (-0.07%)
     
  • USD/JPY

    108.4310
    +0.0490 (+0.05%)
     
  • BTC-USD

    50,367.11
    +1,050.93 (+2.13%)
     
  • CMC Crypto 200

    1,019.92
    +76.74 (+8.14%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021 at 5:20 p.m. ET.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005294/en/

Contacts

Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com

Media Contact
Liza Heapes or Vivian Ni
+1 857-302-5663 or +1 857-302-7596
media@beigene.com